Peer-reviewed veterinary case report
How mebendazole moves in dog blood and spinal fluid after one dose
By Yanke, Amy B et al.·Published in Frontiers in veterinary science·2023·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Pharmacokinetics of mebendazole in plasma and cerebrospinal fluid following a single oral dose in healthy dogs.
- Species:
- dog
Plain-English summary
A group of healthy mixed breed dogs was given a single oral dose of mebendazole to see how well it could reach effective levels in their cerebrospinal fluid (CSF) for treating brain tumors. The doses tested were 100 mg/kg and 200 mg/kg, and while some dogs experienced mild gastrointestinal upset like vomiting and diarrhea, these effects were not serious. The study found that a dose of 100 mg/kg could achieve the necessary drug levels in the CSF, but a higher dose of 200 mg/kg provided more consistent results. This research suggests mebendazole could be a potential treatment for gliomas in dogs.
People also search for: dog brain tumor treatment · mebendazole for dogs · dog vomiting after medication · glioma treatment in dogs · mebendazole dosage for dogs
Abstract
Novel therapies are needed for treatment of gliomas. Mebendazole previously demonstrated anti-neoplastic effects on canine glioma cell lines atmean inhibitory concentrations (IC) of 10 ng/mL. Our study aimed to titrate the oral dose of mebendazole necessary to achieve concentrations ≥10 ng/mL in cerebrospinal fluid (CSF) of healthy dogs. We hypothesized that an oral dose up to 200 mg/kg would be necessary. Phase one was a dose titration study using a total of 6 mixed breed dogs that described dose vs. plasma concentrations for 72 h after single oral dosing of either 50 mg/kg ( = 2), 100 mg/kg ( = 2), or 200 mg/kg ( = 2). Based on phase one, phase two dogs (total of 9) received 100 mg/kg ( = 4) or 200 mg/kg ( = 5) orally and blood samples were collected intermittently for 60 h with CSF samples collected intermittently for 24 h. Mebendazole was quantitated in plasma and CSF using high performance liquid chromatography. Median peak plasma concentrations (Cmax) were reached at 7 ± 2 h (100 mg/kg) of 220 ng/mL (81, 283) and at 15 ± 4 h (200 mg/kg) of 147 ng/ml (112, 298). The respective area under the curve (AUC: ng/ml/h) reported as a median was 2,119 (1,876, 3,288) vs. 3,115 (1,559, 4,972). Median plasma concentrations (ng/ml) for 100 vs. 200 mg/kg were 47 (32, 52) vs. 65 (35, 104), respectively. For CSF, the median value for Cmax (at 100 mg/kg vs. 200 mg/kg) was 8 (2, 28) vs. 21 (12, 27) and AUC was 87 (22, 157) vs. 345 (92, 372), respectively. Relative bioavailability in CSF vs. plasma was 4 to 10%. Although several animals demonstrated clinical signs indicative of gastrointestinal upset [i.e., vomiting ( = 2), diarrhea ( = 2), or both ( = 1)], these events were not considered serious. TheICfor gliomas can be reached in CSF at 100 mg/kg ( = 1), however a 200 mg/kg dose yielded more consistent concentrations.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37701529/